IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+11.71%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$302M
AUM Growth
+$302M
(-1.5%)
Cap. Flow
-$35.1M
Cap. Flow
% of AUM
-11.6%
Top 10 Holdings %
Top 10 Hldgs %
44.95%
Holding
160
New
20
Increased
14
Reduced
32
Closed
33
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
$10.5M |
| 2 |
Apogee Therapeutics
APGE
|
$10.1M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$8.15M |
| 4 |
Insmed
INSM
|
$7.95M |
| 5 |
Cogent Biosciences
COGT
|
$7.44M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$11.7M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$10.1M |
| 4 |
Lyra Therapeutics
LYRA
|
$9.29M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$7.86M |
Sector Composition
| 1 | Healthcare | 99.76% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Alector
ALEC
$262M
| $1.26M | 0.24% |
900,000
-50,000
| -5% | -$70K |
|
52
Nuvation Bio
NUVB
$1.01B
| $1.21M | 0.23% |
619,258
| – | – |
|
53
VistaGen Therapeutics
VTGN
$108M
| $1.2M | 0.23% |
601,703
| – | – |
|
|
CYBN
54
Cybin
CYBN
$147M
| $1.18M | 0.23% |
140,475
-256,700
| -65% | -$2.15M |
|
55
Tourmaline Bio
TRML
$601M
| $1.09M | 0.21% |
67,927
| – | – |
|
56
Wave Life Sciences
WVE
$1.53B
| $1.05M | 0.2% |
+161,137
| New | +$1.05M |
|
57
Veru
VERU
$47.6M
| $829K | 0.16% |
1,425,239
| – | – |
|
|
ORKA
58
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $769K | 0.15% |
68,574
-106,426
| -61% | -$1.19M |
|
59
iShares Biotechnology ETF
IBB
$5.69B
| $728K | 0.14% |
+5,755
| New | +$728K |
|
60
Sangamo Therapeutics
SGMO
$163M
| $682K | 0.13% |
1,260,179
-600,000
| -32% | -$325K |
|
61
Immunic
IMUX
$78.8M
| $638K | 0.12% |
914,170
| – | – |
|
62
Inhibrx
INBX
$408M
| $601K | 0.12% |
42,122
| – | – |
|
63
InflaRx
IFRX
$119M
| $557K | 0.11% |
+705,010
| New | +$557K |
|
64
Kezar Life Sciences
KZR
$28.9M
| $490K | 0.09% |
106,901
| – | – |
|
65
VYNE Therapeutics
VYNE
$8.21M
| $479K | 0.09% |
+290,000
| New | +$479K |
|
66
iBio
IBIO
$15.9M
| $458K | 0.09% |
599,913
| – | – |
|
67
MindMed
MNMD
$695M
| $407K | 0.08% |
62,691
| – | – |
|
68
BiomX
PHGE
$14.8M
| $402K | 0.08% |
892,976
| – | – |
|
69
Lyell Immunopharma
LYEL
$213M
| $387K | 0.07% |
43,799
-832,238
| -95% | -$7.36M |
|
|
NYXH
70
Nyxoah
NYXH
$221M
| $379K | 0.07% |
+50,627
| New | +$379K |
|
71
AnaptysBio
ANAB
$569M
| $348K | 0.07% |
+15,662
| New | +$348K |
|
72
Vera Therapeutics
VERA
$1.44B
| $332K | 0.06% |
+14,096
| New | +$332K |
|
73
Zymeworks
ZYME
$1.12B
| $314K | 0.06% |
+25,000
| New | +$314K |
|
74
Acumen Pharmaceuticals
ABOS
$82.4M
| $308K | 0.06% |
265,769
| – | – |
|
75
Immatics
IMTX
$649M
| $266K | 0.05% |
+49,396
| New | +$266K |
|